West Pharmaceutical Services, Inc. (NYSE:WST) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 3.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 71,806 shares of the medical instruments supplier’s stock after selling 2,313 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.10% of West Pharmaceutical Services worth $25,287,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Portside Wealth Group LLC boosted its stake in shares of West Pharmaceutical Services by 1.2% during the 4th quarter. Portside Wealth Group LLC now owns 2,675 shares of the medical instruments supplier’s stock worth $942,000 after acquiring an additional 33 shares in the last quarter. Peninsula Asset Management Inc. boosted its stake in shares of West Pharmaceutical Services by 0.4% during the 4th quarter. Peninsula Asset Management Inc. now owns 9,580 shares of the medical instruments supplier’s stock worth $3,373,000 after acquiring an additional 35 shares in the last quarter. Addison Advisors LLC boosted its stake in shares of West Pharmaceutical Services by 28.9% during the 4th quarter. Addison Advisors LLC now owns 183 shares of the medical instruments supplier’s stock worth $64,000 after acquiring an additional 41 shares in the last quarter. Balentine LLC boosted its stake in shares of West Pharmaceutical Services by 4.4% during the 3rd quarter. Balentine LLC now owns 1,016 shares of the medical instruments supplier’s stock worth $381,000 after acquiring an additional 43 shares in the last quarter. Finally, Raymond James Trust N.A. boosted its stake in shares of West Pharmaceutical Services by 1.6% during the 4th quarter. Raymond James Trust N.A. now owns 2,869 shares of the medical instruments supplier’s stock worth $1,010,000 after acquiring an additional 45 shares in the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at West Pharmaceutical Services

In other news, CAO Chad Winters sold 815 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $358.82, for a total transaction of $292,438.30. Following the completion of the sale, the chief accounting officer now owns 1,309 shares in the company, valued at approximately $469,695.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CAO Chad Winters sold 815 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $358.82, for a total value of $292,438.30. Following the completion of the sale, the chief accounting officer now owns 1,309 shares in the company, valued at approximately $469,695.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Eric Mark Green sold 66,000 shares of West Pharmaceutical Services stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the sale, the chief executive officer now owns 152,908 shares of the company’s stock, valued at approximately $56,063,718.20. The disclosure for this sale can be found here. Insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Trading Down 0.1 %

Shares of West Pharmaceutical Services stock opened at $314.76 on Friday. The company has a current ratio of 2.61, a quick ratio of 1.95 and a debt-to-equity ratio of 0.03. The firm’s 50-day moving average price is $361.29 and its 200 day moving average price is $362.79. West Pharmaceutical Services, Inc. has a twelve month low of $310.42 and a twelve month high of $415.73. The firm has a market capitalization of $22.93 billion, a PE ratio of 41.53, a P/E/G ratio of 5.57 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last released its earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.27. West Pharmaceutical Services had a net margin of 19.42% and a return on equity of 20.57%. The business had revenue of $695.40 million for the quarter, compared to analyst estimates of $670.62 million. During the same period last year, the company posted $1.98 EPS. The business’s revenue was down 3.0% on a year-over-year basis. On average, sell-side analysts predict that West Pharmaceutical Services, Inc. will post 7.76 EPS for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 7th. Stockholders of record on Wednesday, July 31st will be issued a dividend of $0.20 per share. The ex-dividend date of this dividend is Wednesday, July 31st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.25%. West Pharmaceutical Services’s dividend payout ratio is currently 10.55%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on WST shares. UBS Group lowered their target price on shares of West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating on the stock in a research note on Friday, February 16th. KeyCorp raised their price target on shares of West Pharmaceutical Services from $440.00 to $470.00 and gave the company an “overweight” rating in a research note on Tuesday, February 13th. Finally, StockNews.com lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Friday, February 16th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $435.20.

Get Our Latest Research Report on West Pharmaceutical Services

West Pharmaceutical Services Profile

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Read More

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.